MANAGEMENT TEAM
GREGG PETERSON / CHIEF EXECUTIVE OFFICER
Gregg has over 20 years in healthcare research developing pharmaceutical, biologic, medical device and combination products from ideation to product launch. His extensive experience running Phase I-III clinical trials has led to 20+ agency approvals and 11 product launches across the US, EU and AsiaPac. At Allergen, Gregg was the R&D Program Lead for a global product franchise. He is a veteran of multiple startup biotechnology companies and holds a B.S. from University of Puget Sound and a M.A. from the Medical College of Wisconsin.
JEFFREY BECKER, MD / CHIEF SCIENTIFIC OFFICER
Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use. As one of the first MDs in U.S. administering and documenting ketamine for depression in the clinic, he is a world recognized speaker and expert in the clinical use of ketamine. His expertise led to development of an effective nutraceutical product addressing NMDA-receptor abnormalities. He studied Medicine at UCLA and maintains a clinical practice focused in Functional Psychiatry and novel treatment approaches to mental health challenges.
CORPORATE ADVISORS
WILSON, SONSINI, GOODRICH & ROSATI - IP Attorneys
Led by partner Matthew Bresnahan, WSGR is preparing and filing Bexson’s patent applications, as well as counseling the company's IP strategy. The WSGR team has extensive experience helping life science and technology companies with all aspects of intellectual property, patent prosecution, licensing and litigation.
SCILUCENT - Regulatory Affairs & Toxicology Consulting Team
SciLucent’s team of consultants has vast experience developing innovative pharmaceuticals, medical devices, combination products and dietary supplement ingredients. SciLucent advises Bexson on regulatory affairs, preclinical science strategy and toxicology.
IQVIA - Contract Research Organization
JASON WALLACH, PhD - Consultant, Medicinal Chemistry
IQVIA, formerly Quintiles, has global expertise across almost all R&D functions as a large CRO. IQVIA has served Bexson in successful Orphan regulatory strategy and submissions. IQVIA’s Orphan Drug Unit emerged from the 2017 acquisition of Coté Orphan, a specialty consulting firm founded by former FDA head of the Office of Orphan Products Development, Dr. Tim Coté. This group has an excellent pedigree in orphan consulting with >95% success rate in orphan designation applications.
Dr. Wallach is appointed at the Substance Use Disorders Institute at University of the Sciences and at Cooper Medical School of Rowan University. With over a decade of research experience studying N-methyl-D-aspartate receptor (NMDAR) antagonists, Dr. Wallach’s is a world recognized expert in the chemistry and pharmacology of dissociative drugs including ketamine, with numerous peer-reviewed publications and book chapters. His focus on the therapeutic potential of this drug class in neurological and psychiatric disorders includes the design, synthesis and investigation of over 100 novel potential NMDAR antagonists.
THOMAS ECKRICH, PD – Consultant, Chemistry Manufacturing & Controls
After gaining substantial experience with a Chemistry PhD from Harvard University and 30 years of work at Eli Lilly and Company, Dr. Eckrich began a private consulting firm. Tom brings expertise in process chemistry strategy, CMC, material and technology source development and management to Bexson's project.
CLINICAL ADVISORS
JOSEPH SHURMAN, MD
Dr. Shurman is Chair of Pain Management at Scripps Memorial Hospital, La Jolla, CA and is a world recognized expert is pain management. He is board certified in anesthesiology, a diplomate of the American Academy of Pain, a member of the California Society of Anesthesiologists Committee on Pain Medicine, and a former clinical assistant professor at the University of California, San Diego.
JOSHUA PRAGER, MD, MS
Dr. Prager serves on the Faculty Executive Committee at the David Geffen School of Medicine at UCLA, and is past Chair of the CRPS Group for the International Association for the Study of Pain (IASP) and past President of the North American Neuromodulation Society. He is a world recognized expert in the etiology and treatment of CRPS with ketamine protocols. He is triple board-certified in anesthesiology, internal medicine and pain medicine, and is director of the Center for the Rehabilitation of Pain Syndromes.